La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Steve Mahoney

Amministratore delegato

US$13.0m

Compenso totale

Percentuale dello stipendio del CEO	0.9%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Mahoney rispetto agli utili di Viridian Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 13.02M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 1.38M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Steve con le performance aziendali.

AMMINISTRATORE DELEGATO

Steve Mahoney (53 yo)

less than a year

Mandato

US$13,022,654

Compensazione

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	Nessun dato
Seth Harmon	Senior VP of Finance and Accounting	less than a year	US$6.67m	0.0013% $ 23.3k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	Nessun dato
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Vahe Bedian	Co-Founder & Scientific Advisor	no data	Nessun dato	Nessun dato
Jennifer Tousignant	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Melissa Manno	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Anthony Casciano	Chief Commercial Officer	1.4yrs	Nessun dato	Nessun dato
Thomas Ciulla	Chief Medical Officer	1.7yrs	Nessun dato	0.0010% $ 17.8k

0.9yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di 0K1R non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	Nessun dato
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Arlene Morris	Independent Director	6.7yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Stefanie Dimmeler	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Jeffery Molkentin	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Eva van Rooij	Scientific Advisory Board Member	no data	Nessun dato	Nessun dato
Tomas Kiselak	Independent Chairperson of Board	3.9yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	3.2yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	3.9yrs	US$471.83k	0% $ 0

3.9yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0K1R sono considerati esperti (durata media dell'incarico 3.8 anni).

Viridian Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Recent updates

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

First half 2024 earnings released: US$1.82 loss per share (vs US$2.88 loss in 1H 2023)

New major risk - Revenue and earnings growth

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought US$101k worth of stock

President recently bought US$160k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

High number of new and inexperienced directors

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$1.26 loss in 3Q 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

High number of new and inexperienced directors

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media